Sewon Cellontech세원셀론텍’s manufacturing technology of CartiZol (collagen-based tissue supplement material) has completed its patent registration in Canada.
The patented technology, called the "manufacturing and using composition for restoring cartilaginous tissue,” turns it into an injection, which can help reconstruct joint cartilaginous tissues effectively, company officials said.
The biocompatible bio-collagen, which is most similar to the components of articular cartilage, can be injected directly into the damaged area with just a needle and without a surgical incision.
CartiZol카디졸 complements the weaknesses of the existing products for temporary pain relief such as hyaluronic acid filler, and restores patient's function and reduces costs.
"It is meaningful to have a patent right in Canada where the market for orthopedic medical devices is growing rapidly because of population aging, and is serving as the beachhead for advancing to the North American market, one of the largest medical equipment markets in the world," a company official said. “We are looking forward to enlarging our market share for joint injections."
<© Korea Biomedical Review, All rights reserved.>